Federal prosecutors accuse Michael McMillan of directing a reimbursement-driven wound-care operation that allegedly paid providers and sales representatives unlawful incentives, generated approximately $268 million from government healthcare programs, and converted disputed proceeds into valuable personal property.
WASHINGTON, DC — Michael McMillan faces a nine-count federal indictment alleging that his Protectus network used skin-substitute products, reimbursement-linked provider profits, misleading claim information, and sales commissions to generate extraordinary payments from Medicare and two military-connected healthcare programs.
The case combines three related but legally distinct theories, beginning with conspiracy to commit healthcare fraud, continuing with conspiracy to defraud the United States and pay healthcare kickbacks, and concluding with seven alleged transactions involving property derived from unlawful activity.
Federal prosecutors contend that McMillan, a 55-year-old Las Vegas resident, controlled six Nevada companies that recruited medical providers, supplied products without upfront payment, assisted with reimbursement claims, and collected money only after government programs approved those claims.
According to the indictment, that contingent arrangement allowed participating providers to retain approximately thirty to forty percent of each successful reimbursement, an economic benefit prosecutors characterize as illegal remuneration intended to influence product selection and government-program billing.
McMillan has not been convicted; the indictment represents allegations rather than evidence, and prosecutors must prove every element beyond a reasonable doubt while his lawyers may challenge the government’s interpretation of contracts, communications, invoices, claims, payments, and financial transactions.
Nine Counts Organize the Government’s Case
The Justice Department’s Northern District of Texas announcement summarizes charges involving healthcare fraud, illegal kickbacks and bribes, and monetary transactions in criminally derived property, while reporting approximately $35 million in seized assets connected with the investigation.
Count One charges conspiracy to commit healthcare fraud under federal statutes governing agreements to defraud healthcare benefit programs, rather than charging McMillan with nine interchangeable versions of one generalized scheme involving medical products and reimbursement.
Count Two charges a separate conspiracy to impair federal oversight and to offer or pay kickbacks and bribes connected with items reimbursable by a federal healthcare program, giving prosecutors an additional route focused upon remuneration and government functions.
Counts Three through Nine charge McMillan with knowingly engaging in monetary transactions exceeding $10,000 using property allegedly derived from the two charged conspiracies, a category commonly described as transactional money laundering although the indictment uses more exact statutory language.
Count One Centers Upon Allegedly Fraudulent Claims
Prosecutors allege that, from approximately May 2019 through at least February 2026, McMillan knowingly joined others in a plan to obtain government healthcare money through materially false representations connected with skin substitutes applied to beneficiaries’ wounds.
The government’s fraud theory does not depend solely upon whether a product physically reached a patient, because the indictment emphasizes claims allegedly induced through kickbacks and acquisition-price representations that prosecutors say concealed each provider’s true economic cost.
Under that theory, claims became fraudulent when undisclosed financial arrangements and inaccurate pricing information affected eligibility or payment, even where a provider performed a wound-care procedure and submitted documentation describing a product that had actually been supplied.
The defense may contest materiality, knowledge, program guidance, medical necessity, independent clinical judgment, product value, and responsibility for final submissions, requiring prosecutors to connect McMillan personally with the statements and decisions supporting the charged agreement.
Count Two Focuses Upon Kickbacks and Federal Oversight
The second count alleges that McMillan conspired to obstruct the lawful administration and oversight of Medicare while offering and paying remuneration to induce providers to purchase, order, arrange for, or recommend skin-substitute items reimbursed by federal programs.
Prosecutors characterize provider retention as a kickback because Protectus allegedly invoiced only after successful reimbursement, accepted no payment following denial, and ordinarily collected sixty to seventy percent while knowingly leaving the remainder with the billing practice.
The charging document also treats reimbursement-based sales commissions as illegal inducements, alleging that representatives recruited medical practices, explained the profit-sharing opportunity, and received compensation calculated from money Protectus collected after the providers they recruited secured government payments.
Because federal conspiracy law examines agreement, purpose, knowledge, and overt conduct, prosecutors will use emails, invoices, commission reports, payments, meetings, claim instructions, and internal approvals to argue that the challenged arrangements reflected coordinated criminal intent rather than accidental noncompliance.
Defense counsel can answer that discounts, credit terms, rebates, commissions, billing support, and risk-sharing arrangements may possess legitimate commercial explanations, while arguing that prosecutors have not established willful participation in an agreement to violate clearly understood legal duties.
Protectus Operated Through Six Allegedly Related Companies
The indictment identifies Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC as Nevada entities McMillan allegedly owned and controlled throughout the charged period.
Prosecutors use the collective name Protectus when describing product distribution, provider invoices, employee communications, claim assistance, representative compensation, and receipts, although each company’s records, contracts, personnel, accounts, and activities may remain relevant to individual allegations.
Corporate affiliation alone does not prove criminal conduct, because commonly controlled companies can serve lawful operational purposes, but prosecutors may use shared ownership, coordinated employees, intercompany transfers, and centralized approvals to establish McMillan’s alleged direction and knowledge.
The defense can demand transaction-specific proof identifying which entity supplied each product, issued each invoice, assisted each claim, paid each representative, received each provider transfer, and funded each purchase associated with the seven property counts.
Providers Allegedly Received Products Without Upfront Cost
According to prosecutors, Protectus offered skin substitutes to physicians, podiatrists, nurse practitioners, and other medical providers without requiring payment before treatment, thereby shifting immediate product cost away from practices considering the reimbursable wound-care items.
If Medicare, TRICARE, or CHAMPVA denied a claim, Protectus allegedly charged the provider nothing, while an approved claim triggered an invoice calculated as a percentage of reimbursement rather than a conventional fixed acquisition price established before product use.
That structure allegedly guaranteed provider profit because a practice could retain thirty to forty percent of successful reimbursement without bearing product cost following denial, creating what prosecutors describe as a powerful financial inducement favoring Protectus products.
The indictment names five anonymized providers in Texas, California, and Utah, but anonymity within the public charging document does not determine whether those individuals will become witnesses, cooperating participants, separately charged defendants, or subjects of continuing investigation.
The Alleged Money Flow Reached $268 Million
The indictment alleges that government programs paid approximately $268 million on challenged skin-substitute claims, with approximately $174 million reaching McMillan’s Protectus companies and approximately $94 million remaining with medical providers under the disputed percentage arrangement.
Those figures describe the prosecution’s asserted distribution of government payments, meaning the alleged provider share and Protectus share together account for the approximately $268 million total rather than representing additional losses stacked above that amount.
Prosecutors separately allege that Protectus paid approximately $27 million in reimbursement-linked compensation to sales representatives, but those payments appear to have come from Protectus receipts and therefore should not be added again when describing total program disbursements.
Whether the entire $268 million ultimately qualifies as criminal loss may depend upon sustained counts, claim eligibility, truthful pricing, medical value, kickback consequences, repayments, denials, credits, and the evidence available for individual providers and beneficiaries.
Box 19 Pricing Is Central to the Fraud Allegation
The charging document says providers were required to report actual acquisition prices after discounts, rebates, refunds, and other adjustments within Box 19 of relevant Medicare claims, making truthful disclosure of economic cost central to the reimbursement process.
Prosecutors allege that McMillan or Protectus employees submitted, assisted, or counseled submissions containing inflated prices that did not reflect what providers ultimately owed after Protectus applied reimbursement-contingent invoices and allowed practices to retain substantial percentages.
That allegation links the kickback theory with the fraud theory, because the same retained payment prosecutors call remuneration also allegedly demonstrates why the reported acquisition price overstated the provider’s true obligation for a supplied product.
Defense lawyers may examine shifting claim instructions, contractor guidance, invoice timing, terminology, billing responsibility, disclosure conventions, provider reliance, and regulatory complexity to dispute whether any representation was knowingly false, material, or attributable to McMillan.
Emails and Invoices Supply Alleged Overt Acts
One invoice cited by prosecutors recorded a total collection of $53,625.60, stated that a medical provider would keep $16,087.68, and identified $37,537.92 as due to Protectus Technologies, illustrating the alleged percentage division in explicit financial terms.
Another communication allegedly followed a provider’s complaint that an invoice reflected thirty-five percent profit instead of a new forty-percent arrangement, after which McMillan forwarded the message internally and directed that the discrepancy be corrected.
Prosecutors also describe commission reports tied to provider payments, including communications explaining that representatives could receive compensation only after Protectus learned an insurance payment had arrived and collected the corresponding provider invoice in full.
These records may give the government unusually concrete evidence of calculations and timing, but the defense can challenge context, authorship, terminology, completeness, hearsay treatment, business meaning, and whether any cited communication demonstrates criminal knowledge.
A March 2024 Meeting Allegedly Explained the Economics
The indictment says McMillan met with a podiatrist during March 2024 and explained that Protectus offered medical providers an average thirty-five percent rebate, using projected monthly Medicare collections to illustrate the practice’s potential financial return.
Under the example attributed to McMillan, a provider collecting $180,000 monthly from skin-substitute claims could keep approximately $63,000, a calculation prosecutors will likely present as evidence that provider profit served as an intentional recruitment feature.
Prosecutors further allege that McMillan said he reviewed every Medicare claim to ensure Protectus products were billed above what providers actually paid, a statement whose wording, context, recollection, interpretation, and admissibility may become heavily contested.
If admitted and credited, the meeting could connect McMillan directly with claim pricing and provider remuneration, while the defense may argue that lawful reimbursement education, imprecise terminology, edited context, or witness reliability changes its meaning.
Sales Representatives Allegedly Expanded the Network
The government alleges that sales representatives recruited practices throughout the Northern District of Texas and elsewhere, explained the provider profit split, promoted Protectus skin substitutes, and received percentages based upon money generated by their recruited accounts.
Commission-based sales compensation is common across lawful industries, yet healthcare arrangements can create criminal exposure when remuneration is knowingly designed to induce orders, purchases, recommendations, or referrals for items payable by federal healthcare programs.
Prosecutors will therefore need to establish more than aggressive selling or percentage compensation, connecting representative payments with an unlawful purpose while showing McMillan knowingly approved the arrangements and intended them to influence reimbursable medical decisions.
The defense may distinguish product marketing from patient referral activity, challenge whether representatives controlled clinical choices, and argue that compensation rewarded legitimate sales services without establishing the willful intent required for a federal kickback conspiracy.
The Money-Laundering Counts Address Later Purchases
Counts Three through Nine do not merely repeat the alleged fraud and kickback agreements, because each count identifies a later monetary transaction that prosecutors contend involved more than $10,000 in proceeds derived from those specified unlawful activities.
The applicable transactional statute differs from a concealment-based laundering theory, focusing upon knowing participation in qualifying financial transactions involving criminally derived property rather than necessarily requiring proof that each purchase was structured to hide its source.
Prosecutors must nevertheless prove that the relevant property came from specified unlawful activity, that McMillan knew it represented proceeds from some criminal offense, and that each transaction met the jurisdictional and monetary requirements governing the charged statute.
The defense can contest tracing, knowledge, account ownership, legitimate deposits, financing, commingling, transaction characterization, and the asserted connection between particular healthcare receipts and every residence, vehicle, or aircraft payment prosecutors publicly identified.
Seven Transactions Total Approximately $6.28 Million
Count Three identifies approximately $1,010,166 connected with a Dallas condominium during December 2021, while Count Four identifies a $60,000 transaction involving a 2023 Lamborghini Urus Performante during July 2023, according to prosecutors.
Count Five alleges approximately $260,466 connected with property on Oakmont Hills Lane in Las Vegas during September 2023, adding another real-estate payment to the government’s account of disputed healthcare proceeds becoming durable personal assets.
Count Six identifies approximately $1.3 million for property in Simpsonville, Kentucky, during May 2024, while Count Seven alleges approximately $1,041,625 connected with a Del Mar, California, property during October 2024.
Count Eight concerns a $50,000 transaction involving a 2023 Cadillac Escalade V-Series during March 2025, although the amount identified in the count should not automatically be reported as the vehicle’s complete purchase price.
Count Nine alleges approximately $2,557,325 was paid during September 2025 for a 1997 Cessna Citation VII through an account attributed to Elite Elevated Enterprises LLC, making the aircraft the largest individually charged transaction.
Together, the seven identified amounts total about $6.28 million, but that figure reflects charged transactions rather than the full value of every listed asset, the government’s alleged loss, or the amount ultimately recoverable through forfeiture.
Seized Assets and Final Forfeiture Are Different
Federal authorities announced approximately $35 million in seized assets, while the indictment separately seeks a money judgment and identifies five real-estate interests that prosecutors contend may be forfeitable following conviction and required judicial findings.
Pretrial seizure generally preserves disputed property while litigation proceeds, whereas permanent criminal forfeiture usually follows conviction and requires a legally sufficient connection between property and sustained offenses, subject to procedural protections and court review.
Mortgages, liens, partial ownership, depreciation, financing, legitimate funds, operating costs, taxes, and third-party claims can reduce recoverable value, meaning the announced seizure estimate should not be described as restitution already returned to government programs.
McMillan may challenge probable cause, tracing, valuation, ownership, commingling, and statutory coverage, while spouses, lenders, companies, investors, or other claimants may separately assert legally protected interests in homes, vehicles, aircraft, accounts, or proceeds.
Medicare Was Not the Only Alleged Victim Program
Although Medicare dominates the public description, the indictment also identifies TRICARE and CHAMPVA as affected healthcare benefit programs, extending the allegations to systems serving active-duty personnel, military families, retirees, veterans, survivors, and qualifying dependents.
That multi-program scope helps explain the participation of investigators from the Federal Bureau of Investigation, the Health and Human Services Office of Inspector General, the Defense Criminal Investigative Service, and the Department of Veterans Affairs Office of Inspector General.
Each program operates under its own administrative framework, but prosecutors allege the programs shared essential requirements concerning medical necessity, truthful claim information, and ineligibility of items or services procured through illegal healthcare kickbacks.
The defense may require program-specific proof rather than accepting generalized healthcare assertions, particularly where coverage rules, contractors, forms, pricing instructions, claim processing, beneficiary status, or provider communications differed across Medicare, TRICARE, and CHAMPVA.
The Case Drew Immediate Regional Attention
An NBC 5 Dallas-Fort Worth report on the regional enforcement action highlighted the McMillan allegations alongside six unrelated North Texas prosecutions, emphasizing the wound-care claim total, luxury purchases, private aircraft, and broader focus on elderly and military-connected beneficiaries.
The McMillan prosecution formed part of the 2026 National Health Care Fraud Takedown, while Northern District of Texas authorities announced thirteen defendants across seven cases involving more than $365 million in allegedly fraudulent billing.
McMillan’s approximately $268 million matter represented the largest individually announced claim figure within that regional group, yet accusations involving unrelated defendants cannot prove his conduct, intent, knowledge, or responsibility for any charged transaction.
Coordinated announcements can demonstrate enforcement scale and interagency cooperation, but courts must prevent campaign-wide figures, unrelated patient allegations, and other defendants’ property from substituting for admissible evidence specific only to McMillan and Protectus.
Potential Penalties Depend Upon Sustained Counts
Under the cited statutes, Count One carries a maximum prison term of ten years, Count Two carries five years, and each Section 1957 transaction count carries ten years, although fines and forfeiture may also apply.
Maximum penalties do not predict an actual sentence, because any outcome would depend upon convictions, proven loss, McMillan’s role, criminal history, obstruction findings, acceptance of responsibility, victim evidence, advisory guidelines, statutory rules, and judicial discretion.
The seven transaction counts also require individualized findings, so proof that one purchase involved criminally derived property would not automatically establish the unlawful source, knowledge, amount, or jurisdictional elements associated with every other charged asset.
Restitution and forfeiture would require additional analysis of victim loss, legitimate value, traceable proceeds, recovered property, competing ownership interests, credits, repayments, and the relationship between financial remedies imposed under distinct applicable federal statutes.
Defense Challenges Could Reshape the Narrative
McMillan’s lawyers may argue that Protectus supplied useful products through legitimate distribution relationships, offered permissible commercial terms, relied upon professional billing practices, and allowed licensed providers to exercise independent medical judgment for individual patients.
They may challenge whether percentage retention constituted prohibited remuneration, whether any regulatory safe harbor or discount principle applied, whether Box 19 guidance clearly addressed the arrangement, and whether McMillan knowingly intended false submissions.
Counsel can also dispute witness credibility, cooperation incentives, email context, invoice interpretation, commission terminology, meeting accounts, electronic evidence, claim samples, expert methodology, and the assumption that unusually profitable business activity necessarily demonstrates fraudulent intent.
Transaction counts, lawful earnings, loans, investment proceeds, financing records, prior account balances, corporate purposes, and competing tracing methods could undermine the government’s attempt to connect particular purchases with specified unlawful activity.
None of those potential arguments establishes innocence by itself, just as the government’s detailed allegations do not establish guilt, because the decisive record will emerge through discovery, motions, stipulations, testimony, exhibits, cross-examination, and judicial rulings.
Reputation Consequences Begin Before Trial
A public indictment combining Medicare, military healthcare programs, a $268 million payment allegation, approximately $35 million in seized assets, luxury vehicles, expensive residences, and a private aircraft can reshape search results long before courtroom testing begins.
Individuals and organizations facing that imbalance may need disciplined crisis public-relations management that distinguishes allegations from adjudicated facts, protects confidential information, corrects verifiable inaccuracies, coordinates authorized statements, and avoids commentary that could undermine legal strategy.
Longer-term reputation-rebuilding strategies can document procedural developments, verified compliance reforms, independent audits, leadership decisions, and final outcomes without concealing material facts or inaccurately presenting an unresolved prosecution as either proven guilt or complete exoneration.
McMillan, individual Protectus entities, providers, representatives, employees, beneficiaries, creditors, and property claimants may occupy different legal positions, making tailored communication essential whenever a collective response could imply shared culpability or contradict formal court submissions.
What Happens Next in the Michael McMillan Case
Pretrial litigation may address discovery volume, claim sampling, provider contracts, reimbursement guidance, search authority, seized property, electronic communications, expert testimony, witness cooperation, venue, evidentiary admissibility, corporate records, and competing forensic financial tracing methods.
Prosecutors will attempt to prove that provider profit and representative compensation were deliberate inducements embedded in a claim system that used inflated acquisition-price information, while the defense will seek lawful explanations for each commercial and billing practice.
Any plea agreement would require judicial review and an adequate factual basis, while a trial would demand count-specific proof allowing jurors to evaluate the two alleged conspiracies separately from each of the seven property transactions.
If convictions occur, later proceedings may determine loss, restitution, forfeiture, third-party ownership, substitute assets, advisory sentencing calculations, and appropriate punishment, ensuring that a verdict would not automatically resolve every disputed financial issue in the prosecution.
If McMillan is acquitted or particular counts fail, related restraints and forfeiture claims may require reconsideration, although the treatment of each asset would depend upon governing orders, evidence, ownership interests, and the legal basis supporting seizure.
Until a jury returns verdicts or another lawful resolution concludes the case, Michael McMillan remains presumed innocent, every allegation remains open to adversarial testing, and prosecutors retain the burden of proving all nine federal counts beyond a reasonable doubt.
